September 25, 2020
Weil advised Advent International in connection with the acquisition of Sundia MediTech Company, Ltd. (Sundia), a leading contract research and manufacturing organization in China. The transaction is a bolt-on acquisition to BioDuro, in which Weil also advised Advent International in January 2019. Following this transaction, BioDuro will combine with Sundia (hereafter operating as BioDuro-Sundia) and become one of the largest contract research, development and manufacturing organizations with major operations in China and the United States.
The Weil team was led by Private Equity partner Charles Ching and included associates Kenny Yu, Kevin Wang, Benjamin Yao and Carol Jia, and legal consultant Wenyuan Zhao; Tax partner Noah Beck and counsel Gary Silber; Executive Compensation & Benefits partner Amy Rubin and Lauren Sawyer (Not Yet Admitted in New York); and Antitrust partner Douglas Nave and counsel Neil Rigby.
For further information on the transaction, please click here.